Kazia Therapeutics Annual Reports 2023

30 DIRECTORS’ REPORT At-The-Market (ATM) Facility During the month of July 2023 through to August 8 2023, the company raised total proceeds for the period of US$1.019 million (AU$1.541 million). increasing the total shares outstanding to 236,349,374. Shares issued under the ATM are issued at the spot market price, with no discount, no accompanying warrants or options, and with banking fees approximately half of those associated with more traditional financing methods. Resignation of Chairman Kazia announced the resignation of Mr. Iain Ross as Chairman and non-executive director on 11 August 2023. The Board of Directors has elected Dr John Friend as Interim Chairman. No other matter or circumstance has arisen since 30 June 2023 that has significantly affected, or may significantly affect the consolidated entity’s operations, the results of those operations, or the consolidated entity’s state of affairs in future financial years. Significant changes in the state of affairs There were no significant changes in the state of affairs of the consolidated entity during the financial year. Likely developments and expected results of operations The consolidated entity has a reasonable expectation that over the course of the coming 12 months: • Interim results will be reported from the phase II PNOC clinical trial of paxalisib in combination with ONC201; • Interim results will be reported from the phase II clinical trial of paxalisib in combination with trastuzumab in breast cancer metastases; • Interim results will be reported from the phase II genomically-guided study of paxalisib in brain metastases; • Interim results will be reported from the phase I study of paxalisib in combination with radiotherapy in brain metastases; and • Final data will be reported from the phase I study of paxalisib in children with diffuse intrinsic pontine glioma (DIPG). Environmental, social and governance (ESG) report Environmental The consolidated entity is not subject to any significant environmental regulation under Australian Commonwealth or State law. We are considering ways in which environmental impacts can be monitored however we do not foresee a material impact. Kazia’s head office is located in one of the most sustainable carbon neutral commercial precincts. The serviced office is located in a building with a five star NABERS energy rating. Social and Governance Social and governance matters cover a vast range of potential issues including responsible business policies. Our policies set out our commitment to high social standards. The following policies are in place and available on our website: • Anti-Corruption Compliance • Continuous Disclosure • Corporate Governance • Expanded Access • Shareholder Communications • Whistleblower Employees The consolidated entity aims to ensure that it has a safe operating environment with an inclusive and diverse culture and the best talent and skills for our future success. The following employee policies are in place: • Code of Business Conduct & Ethics • Recruitment and retention • Inclusion and diversity • Parents returning to work • Education and training • Employee Share Option Plan • Health and safety • Whistleblowing • Equal Employment Opportunity and Diversity • Harassment and Discrimination • Anti-corruption and anti-bribery policies • Public disclosures • Securities trading • Scientific integrity